Non-invasive Diagnostics of Pulmonary Hypertension With Dual Energy Computed Tomography
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT01607489|
Recruitment Status : Completed
First Posted : May 30, 2012
Last Update Posted : July 17, 2017
|Condition or disease||Intervention/treatment||Phase|
|Pulmonary Arterial Hypertension||Radiation: Dual-energy computed tomography investigation||Not Applicable|
Pulmonary arterial hypertension (PAH) is a rare, life-threatening disease. It is characterized by the elevation of pulmonary arterial pressure and pulmonary vascular resistance. A remodeling of small pulmonary vessels characterized by the proliferation of the adventitia, the hypertrophy of the media and fibrosis of the intima can be observed on the microscopic level.
Non-invasive techniques for hemodynamic assessment and identification of early pulmonary vascular remodeling and pulmonary hypertension have a marked practical advantage as compared to invasive right heart catheterization, however, their accuracy and reliability is not well established.
In the present study the investigators examine patients who underwent right heart catheterization and are scheduled for a thorax CT with an additional dynamic contrast-enhanced DE-CT protocol and derive established parameters for the diagnosis of PAH as well as novel parameters from the CT scans. These are compared to results from the right-heart catheterization and other investigations routinely carried out on these patients.
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||25 participants|
|Intervention Model:||Single Group Assignment|
|Masking:||None (Open Label)|
|Official Title:||Non-invasive Diagnostics of Pulmonary Hypertension With Dual Energy Computed Tomography - Pilot Study|
|Study Start Date :||June 2011|
|Actual Primary Completion Date :||March 2017|
|Actual Study Completion Date :||March 2017|
pulmonary vascular disease
Dual-energy computed tomography investigation
Radiation: Dual-energy computed tomography investigation
1x 20ml Ultravist (370mg J/ml)3-5ml/s,
1x 70ml Ultravist (370mg J/ml)3-5ml/s Contrast agent administration
Other Name: CT
- Pulmonary blood flow and volume determined by dual energy computed tomography [ Time Frame: measurements with right heart catheterisation within 1 month ]determination of differences in pulmonary blood flow and volume of pulmonary hypertension patients
- Comparison of dual energy computed tomography derived data with clinical findings of pulmonary hypertension patients [ Time Frame: measurements with right heart catheterisation within 1 month ]comparison of different state or type of pulmonary hypertension
- Lung perfusion heterogeneity determined by dual energy computed tomography [ Time Frame: measurements with right heart catheterisation within 1 month ]quantification of regional perfusion differences in pulmonary hypertension patients
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01607489
|Medical University Graz, Division of Pulmonology|
|Graz, Steiermark, Austria, 8010|
|Principal Investigator:||Horst Olschewski, MD||Medical University of Graz|